The Current Role of the Percutaneous Arteriovenous Fistula for Hemodialysis Access

Krystina N. Choinski, Scott A. Sundick, Ajit G. Rao, Windsor Ting, Peter L. Faries, Rami O. Tadros

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Dialysis is the preferred treatment for patients with end-stage renal disease (ESRD) for the removal of accumulated toxins secondary to compromised renal function. Hemodialysis has traditionally been performed via a surgically created arteriovenous fistula (AVF) or arteriovenous graft (AVG). Novel endovascular techniques have allowed for the creation of percutaneous arteriovenous fistulas for hemodialysis access. Two devices, the Ellipsys® Vascular Access System (Avenu Medical, Inc., San Juan Capistrano, California) and the WavelinQ EndoAVF System (C.R. Bard, Inc., Murray Hill, New Jersey), are currently available for percutaneous AVF creation and investigation of their utility is ongoing. This paper describes the current utilization, differences, and results thus far with these devices and, additionally, investigates the contemporary advantages, disadvantages, and selection criteria for percutaneous AVFs overall.

Original languageEnglish
Pages (from-to)217-224
Number of pages8
JournalSurgical technology international
StatePublished - 28 Nov 2020


Dive into the research topics of 'The Current Role of the Percutaneous Arteriovenous Fistula for Hemodialysis Access'. Together they form a unique fingerprint.

Cite this